Background Smoking cessation is a challenging task with a high risk of relapse. Depending on the choice of medication and duration of therapy, the costs of using a smoking cessation aid can be high. Additionally, these costs are not covered by health insurance in Germany. Information on willingness to use (WTU) and willingness to pay (WTP) for smoking cessation aids is valuable for developing different smoking cessation strategies. Objectives The study analyses WTU and WTP for three pharmacological smoking cessation aids (nicotine replacement therapy (NRT), bupropion and varenicline) among young and middle-aged adults in Germany and attempts to determine their major driving factors. Methods Two cross-sectional internet-based surveys of smokers over 18 years of age were conducted in 2014 and 2015 in Germany. Respondents were asked about smokingrelated issues and WTU and WTP for each therapy. The contingent valuation method with payment cards was used to measure WTP. Descriptive statistics, logistical regression and accelerated failure-time regression models were performed. Results The total sample size is 505. Half of the respondents are willing to use NRT and one-third are willing to use bupropion and/or varenicline. WTU induces positive WTP; however, the magnitude of WTP is beneath the market price. WTU significantly increases with a higher addiction level and if smokers have previously heard about the therapy. Conclusion This study indicates different points to be considered for policy development. Promotion information and improving awareness about medication aids might increase WTU, and development of monetary incentives for young smokers could create a better chance for successful smoking cessation.
Introduction
Smoking is one of the main contributing factors to leading causes of death such as chronic obstructive pulmonary disease, lung cancer and cardiovascular diseases. According to the World Health Organization (WHO), smoking-related conditions are responsible for six million deaths annually [1] . In Germany, smokers account for 26 % of the population, a percentage similar to the smoking prevalence in Europe (28 %) . Most of the current smokers are young and middleaged adults. The smoking rate for these groups is higher than the population-level prevalence: approximately 29 % for young adults (aged 15-24 years) and 37 % for people aged 35-39 years [2] . The WHO also reports that more than half of the smokers in Europe are interested in quitting smoking [3] . According to statistics, over the last year, 21 % of European smokers have tried to quit smoking and the overall percentage of people in Europe who have attempted to stop smoking has reached 63 %.
Owing to the physically and mentally addictive nature of smoking, quitting is a considerable challenge, with a high risk of relapse. To support quitting smoking, various measures are available: psychological counselling (face-toface or via telephone), self-help measures (books, applications and websites), individual or group therapy, and alternative methods such as acupuncture. Additionally, nicotine replacement therapy (NRT), bupropion and varenicline have been found to be effective in supporting smoking cessation [4] . However, in Germany, the cost of these medications is borne by the user, whereas other interventions targeting smoking behaviour are either free of charge or covered by health insurance programs.
Evidence-based clinical practice guidelines for tobacco cessation recommend a combination of pharmacotherapy, physician counselling and social support as a key strategy for smoking cessation [5] . Although usage of medications is included in the recommendations, smokers generally do not use pharmacotherapy. A recent smoking cessation trial in Germany reported that only 1 % of smokers have used prescription drugs like varenicline and bupropion [2] . Information about the number of persons who have used NRT is not available.
Several studies have analysed the cost-effectiveness of pharmacological therapies for smoking cessation; however, the authors point out the need to define a threshold at which a therapy is considered to be cost-effective [6] . Among the several factors that predetermine the choice of a cost-effectiveness threshold is the amount of money that people are willing to spend to gain the benefits of the intervention. Five studies have analysed willingness to pay (WTP) for different pharmacological smoking cessation therapies in different countries [7] [8] [9] [10] [11] . Most of these studies focus on WTP in hypothetical scenarios such as the development of a new effective medication [7] or a smoking cessation therapy that gives a guarantee for stopping smoking [8] .
In Germany, WTP for smoking cessation medication has not yet been investigated. Most of the smokers in Germany are young adults and the German health insurance companies do not reimburse pharmacological smoking cessation therapies, so people must bear the costs of these medications themselves. In these settings, estimation of WTP and investigation of its driving factors might be useful for developing public health programs that target smoking cessation.
In this study, we investigate willingness to use (WTU) and WTP for smoking cessation therapy in young and middle-aged adults in Germany. We focus on three medications which have been approved in Germany as smoking cessation aids: NRT, bupropion and varenicline. NRT is an over-the-counter (OTC) medicine; it exists in different forms such as patches, gum, lozenges, inhalers and nasal sprays [12] . In contrast to NRT, bupropion and varenicline are available only on prescription and are sold in the form of pills. Although all the substances serve to reduce nicotine cravings, they differ in efficacy, drug delivery form, side effects and price. We examine the effects of demographical, socioeconomic and smoking-related characteristics on WTU and WTP for each therapy. In our analysis, we aim to inform development of smoking cessation policies among young people.
Methods

Study Type and Dataset
Two cross-sectional Internet-based studies were conducted in Germany over two periods: between May and August 2014 and between May and June 2015. The major criteria for enrolment in the survey were being a current smoker and age between 18 and 65 years. People who were undergoing a smoking cessation program were excluded from the survey. Participants were recruited actively via mail and passively via social networks, several smoking forums and self-help groups. No incentive was offered for participation in the survey. The study was approved by the Committee for Clinical Ethics of the Hanover Medical School.
Questionnaire
In order to examine WTU and WTP for the three therapies, we developed a questionnaire which included sections on demographic and socioeconomic characteristics and smoking habit issues (see Supplemental Material, Appendix A). It also included questions regarding experience with smoking cessation therapies as well as WTU and WTP for each of the three drugs.
In the first part, respondents were asked questions related to their smoking history and nicotine dependency. Smoking addiction was measured using the Fagerström test [13] . Additionally, participants were asked about the age at which they began smoking, the number of smokers in their social environment (peer group) and whether they wish to quit smoking.
The second part of the questionnaire focused on the pharmacological treatment options and questions about WTU and WTP. To inform respondents about the therapy options, a description of each therapy was provided: Characteristics of the nicotine patches, administration of bupropion or varenicline, and information about intake, dosages, odds of success and potential side effects. Treatment effectiveness rates were based on the mean values obtained from different studies [12, 14] . In the following sequence of therapy-related questions, respondents were asked (1) whether they had heard about the therapy and had experience using the indicated medication; (2) based on the provided information about the therapy, whether they would be willing to use it if it is free of charge; (3) and regardless of the response to the WTU question, whether they would be willing to pay for the medication aid. By including the yes-no question on WTP for all respondents, we sought to prevent misunderstanding. Those who stated 'no' when asked about WTU and 'yes' when asked about WTP were excluded from further analysis.
To measure WTP, the contingent valuation method with payment cards was used. Contingent valuation usually involves asking individuals directly in a survey about the maximum amount of money they are willing to pay to gain the commodity in question [15] [16] [17] [18] . In our survey, respondents were first asked whether they are willing to pay for the therapy, and those who chose 'yes' were asked to choose a range of values within which they are ready to spend for the related therapy. The range of values has been defined according to results from prior interviews with smokers. We asked this group which value ranges they would find understandable and preferable. The common answer was 10-Euro intervals, and the usual reason was that €10 was the amount of money they usually paid for nearly two cigarette packages. Ten-Euro intervals were constructed ascending and descending from a middle interval which included the current market price of the product under consideration. We also constructed the lowest interval as less than a certain amount without giving a certain low boundary in order not to lose information, particularly answers from people who would have omitted choosing an interval if they had not found a proper category. Figure 1 illustrates this process, showing questions that lead to possible response options for WTP. The example is given for NRT and is similar for other therapies, but the WTP intervals were adjusted for each medication. At the end of the questionnaire, respondents were asked to provide information on characteristics such as age, sex, education, current employment status, income and insurance status.
Statistical Analyses
Descriptive statistics were calculated separately for each therapy for the outcome and predictor variables. Determinants of WTU and WTP were assessed for each medication separately using regression methods based on distributional characteristics of the outcomes (see equations in Supplemental Material, Appendix B). According to the design of the questionnaire, the outcomes consisted of three variables of interest for each therapy: (1) WTU, which had two possible values termed 'yes' and 'no'; (2) WTP, which also had two possible values termed 'yes' and 'no'; (3) and ordered WTP, shown as 10-Euro intervals. Only respondents who stated 'yes' when asked if they are willing to pay were asked to choose one of the intervals in accordance with their preferred amount. Therefore, a point value of WTP is uncertain; however, it falls within a particular interval. When interval-censoring occurs, survival analysis can be applied by exchanging a failure time for WTP [19] [20] [21] . Although accelerated failure-time models are not conventional for WTP studies, they allow an analysis of WTP interval bids as dependent variables and have been considered appropriate for dealing with WTP intervals in previous studies [21] [22] [23] [24] [25] . In our study, distribution of upper and lower values of the resultant intervals was better approximated by a Weibull distribution. Therefore, for the regression analysis of the ordered WTP, we used accelerated failure-time models with a Weibull distribution.
For the dichotomous outcomes of WTP and WTU, we applied logit regressions, which are conventional for this type of outcome.
Predictors were chosen in accordance with the related literature, research hypotheses and a backward variable selection procedure. They included age, gender, income, employment, presence of health restrictions due to smoking, willingness to quit smoking, attempts to quit smoking, addiction degree, peer group, having heard about the therapy and experience with usage of related therapy.
All regression analyses were performed using the statistical software R.
Results
Descriptive Statistics
Overall, 1735 participants clicked on the URL to the questionnaire during both periods of the survey; of these, 709 started filling it out and 505 respondents completed it. The total sample consisted of 505 individuals with a mean age of 32.63 years. It also had a well-balanced gender ratio (57.43 % male). The largest part of the sample (68.51 %) had completed their education up to high school. In terms of profession, one-third of the sample (31.88 %) is currently studying, and 55.05 % chose the option 'currently employed', which also includes self-employment.
Smoking addiction level, as assessed using the Fagerström test, was 'low' or 'low-moderate' for most of the sample (61.79 %) and 'moderate' or 'high' for the remainder (38.02 %). Most of the respondents (61.79 %) estimated the proportion of smokers in their social environment (peer group) to be between 11 and 50 %. Around 37 % of the respondents wanted to quit smoking, while the other respondents had not decided yet or did not want to quit (62.7 %).
Further details of respondents' characteristics are given in Table 1 . Responses to the part of the questionnaire about smoking cessation aids show that NRT is better known than bupropion or varenicline. Most of the respondents (87.13 %) reported having heard about NRT, whereas only 12.48 and 13.07 % had heard about bupropion and varenicline, respectively. Responses to the question on experience with usage of the medications showed the same tendency: the greatest proportion of the respondents among those who have attempted to stop smoking (374 out of 505) have used NRT (19.25 %), 1 % have used bupropion and 3 % have used varenicline. The other 76.75 % did not use any pharmacological smoking cessation therapies in their last attempts to stop smoking.
Analysis of WTU for medication when it is free of charge shows that NRT is preferred over the other therapy options: more than half of the respondents expressed their willingness to use NRT and only one-third did so for bupropion and varenicline. Most of these respondents are not willing to quit smoking (77.90 % for NRT, 77.78 % for bupropion and 79.46 % for varenicline).
In contrast to WTU, half as many respondents are willing to pay for pharmacotherapy. Out of the total sample, 20.79 % are willing to pay for NRT and 12.87 % are willing to pay for bupropion and varenicline. The intervals chosen by those who responded 'yes' to WTP show that they do not want to pay the amount of the market price. Most of the respondents (74.28 %) are willing to pay less than €87 for NRT, which is below the market price in Germany. Out of the 105 people who are willing to pay for NRT, 60 also state WTP for varenicline and 46 for bupropion. Although fewer smokers are willing to pay for varenicline (n = 80) and bupropion (n = 65), most of the respondents chose lower price intervals: lower than €96 and €74, respectively. We examined the variation in WTU and WTP for the three alternative medications across different respondent characteristics. The resultant estimates are given in Tables 2, 3, 4 for each therapy. We calculated 95 % confidence intervals (CIs) to estimate the precision of the odds ratios (ORs).
Results for 'Willingness to Use' (WTU) if it is
Free of Charge
Out of 11 variables, six show statistical significance at p \ 0.05 for WTU if the medication is free of charge for NRT, five for varenicline and four for bupropion. Of these, an addiction level has the same effect on the occurrence of the answer 'yes' for all three medications: with its increase, the odds of the positive WTU ('yes') outcome rise. Results also show a few common trends across the therapies: an increasing effect of male gender and a decreasing effect of 'yes' and 'not decided' with regard to willingness to quit. Other determinants of WTU vary across the medications ( Table 2 ). The employment variable shows statistical significance for NRT and varenicline. Compared with employed smokers, smokers who are currently studying or not working are less likely to be willing to use the smoking cessation aid. Being familiar with medication in terms of having heard about or having used it shows an increasing effect on WTU for NRT. Opposite results are obtained for varenicline. Smokers who have used varenicline before are less likely to use it again.
Results for Positive 'Willingness to Pay' (WTP)
We conducted a logit regression to examine the effects of the respondents' characteristics on WTP in the form of binomial data. Resultant ORs are presented in Table 3 . According to the resultant ORs, addiction level has a similar effect on WTP as it does on WTU: people who state stronger addiction are more likely to be willing to pay for a smoking cessation therapy. Willingness to quit shows an opposite decreasing effect on WTP. These results hold for the three therapies. Effects of job, income and experience of usage differ among the medications. For NRT, shifting from employed to not working status has a decreasing effect, and both having heard about NRT and having used it show an increasing effect. Additionally, peer group shows that smokers who have less than 10 % smokers in their social environment are likelier to be willing to pay for NRT as compared to those whose peer group has around 25 % smokers.
Results for bupropion also show a decreasing effect of decreasing income and an increasing effect of presence of health restrictions due to smoking. These variables have similar effects on WTP for varenicline. Additionally, smokers who are studying are likelier to be willing to pay for varenicline compared with smokers who are employed.
Results for WTP Value
Respondents who reported positive WTP also provided responses to the payment card. Values were combined to create interval data on WTP. The resultant samples differ in their sizes among the therapies. These samples are used in the regression analysis of interval WTP, with application of accelerated failure-time models. The Weibull distribution is the best-fitting distribution of the outcome variable for the three samples. Table 4 shows the obtained results and respective sample sizes. In addition to the previous regression results, several determinants of WTP are found for each therapy. For NRT, two variables show statistical significance: gender and addiction level. Men are likelier to be willing to pay more than women. A decrease in addiction level decreases the probability of being willing to pay more. Addiction shows the same effect for varenicline. A shift in peer group from '[50 %' to '26-50 %' increases the probability of a higher WTP value.
For bupropion, presence of health restrictions and a shift from employed to not working status decrease this probability. Additionally, age shows an increasing effect. The ORs show that people who have used bupropion are less likely and people who have used varenicline are more likely to be willing to pay a higher amount for these medications.
Discussion
In this study, we consider three smoking cessation aids which are approved by the European Medicines Agency and the US Food and Drug Administration (NRT, bupropion, andvarenicline), and investigate driving factors of WTU and WTP for each of them among young and middleaged smokers in Germany.
Mainly we aimed to produce an analysis supporting the development of a policy which would target smoking cessation among young adults. Therefore, we focus our investigation on the existing medications which allowed us to compared WTP and current market price [26, 27] . According to our results, the amount which the majority of young and middle-aged smokers are willing to pay is lower than the market price for all therapies. The relatively high price might be related to the low prescription rates of these medications [2] .
In our survey, we included both smokers who stated a willingness to quit smoking and smokers who were not willing to quit smoking. We believe that exclusion of the latter might bring a selection bias into an analysis of smokers' WTP, for instance, when comparing market price with WTP [8] . Furthermore, when a smoking cessation policy is being developed, consideration of those who are not willing to quit is desirable in order to elaborate measures directed towards enhancing motivation to quit smoking, supporting it with provision of information about available medication aids for smoking cessation.
Inclusion of the willingness-to-quit variable in our analysis shows that smokers who indicate willingness to quit are less likely to be willing to use and to pay for smoking cessation aids, contrary to our expectations. This finding is supported by a study previously conducted by Morphett et al. [28, 29] . The authors report that unassisted quitting is frequently described as the best way to quit smoking, and smokers see motivation to quit as the foundation of successful quitting, so that when a smoker is truly motivated, no medication aid is necessary.
Another explanation for this result may relate to our sample, which mostly includes people who indicate a low to moderate addiction level. Low addiction level, according to our results, decreases WTP for smoking cessation aids. The same effect is described by Nguyen at al. [30] , who found in a quantitative analysis that light smokers (1-10 cigarettes per day) are less likely to believe that medications would give them a better chance of quitting, and prefer group counselling.
Overall, in our study, addiction level is found to be one of the major drivers of WTU and WTP. WTU and WTP increase with increasing addiction level. This effect has been already reported by Olsen et al. [15] ; however, the authors applied the Cigarette Dependence Scale (CDS-12) to measure addiction. We used the Fagerström test and support their findings. With regard to this result, policy measures related to pharmacological smoking cessation aids (e.g. distribution and promotion information about them) should target smokers with a high addiction level, as their amount of WTP is not high enough to buy the medications. Furthermore, this group is particularly at risk of contracting a smoking-related disease. Therefore, it is necessary to support these groups of smokers first.
Generally, driving factors of WTP and WTU seem to coincide; however, they differ between therapies. Smokers who have used NRT before are more likely to use it again than are smokers who have not had this experience. For varenicline, this is not the case. This might be because of the discouraging side effects of varenicline. Etter and Schneider indicate that one-third of varenicline users report the side effects as being too strong, while only 13.5 % state the same for NRT [31] .
Additionally, we investigated how the magnitude of WTP varies with individual characteristics of smokers. According to our results, most people are willing to pay for smoking cessation medication at a value less than the market cost in Germany. The average price of NRT is around €87 [32] per month, which, according to our results, is perceived as high: more than 70 % of the respondents state that they are not willing to pay that amount. Other therapy alternatives are similarly perceived as expensive by the majority of smokers. Of the respondents who are willing to pay for bupropion, only 26.15 % have a maximum WTP higher than the market price (€74 per month [32] ). For varenicline, only 11.25 % are willing to pay the market price (€106 per month [32] ) or more. The low magnitude of WTP for pharmacological smoking cessation therapies might be a reason for the very low prescription rate (1 %) for bupropion and varenicline [2] . According to these results, it seems that most young and middle-aged smokers in Germany are not willing to pay the market price for smoking cessation aids. Some changes in this direction might be addressed when developing a public health smoking cessation strategy, e.g. reducing the price of medications or development of co-payment options or bonus payments by health insurance companies on condition of successful quitting.
The results of the analysis show that people who are familiar with NRT therapy are likely to be willing to use it and pay for it. Promoting activities to inform smokers about available support with NRT and provision of accurate safety information can increase WTU [33, 34] . However, knowledge about NRT does not necessarily lead to a higher magnitude of WTP for NRT.
A few limitations of our study should be mentioned. First, we targeted smoking young and middle-aged adults, so the sample is not representative of the German population. Second, the results of the regression for magnitude of WTP should be interpreted with caution because of the small number of respondents who gave intervals for WTP for the therapies. Furthermore, we analyse WTP for existing medications but not hypothetical constructs; therefore, respondents' choices might be biased by awareness of the market price, though we attempted to control for this during the enrolment process. An advantage of analysing existing products is that results can be used to compare WTP with real market prices and to explain statistics like low prescription rate for the medications. Additionally, one methodological limitation is the online form of the survey, as certain population groups are less likely to fill out online questionnaires or do not have Internet access.
Further research with a representative and more heterogeneous sample is needed. Among other research questions, it remains interesting to identify the determinants of low magnitude of WTP among smokers and what policy options would increase WTP to the level of the market price. It is also necessary to explore differences in WTU and WTP between smokers who indicate willingness to quit and those who do not. A qualitative research design might be necessary to identify factors which cause these differences in behaviour. Additionally, investigation of non-monetary incentives for quitting might be needed for a better understanding of the motives and preferences of smokers.
Conclusion
To sum up, this study indicates four main points to be considered for development of a smoking cessation policy which pertains to pharmacological aids. First, it has to target smokers who are both willing to quit and those who are not; however, it is necessary to take into account smokers' perception of their own ability to quit and promote additional support. Second, in order to achieve a better impact, measures should be directed towards smokers with a strong addiction. Third, promotion information and improving awareness about medication aids and their efficacy might increase willingness to use them. Last, WTP for pharmaceutical smoking cessation aids is below the market price for all therapy options; therefore, development of monetary incentives for young smokers can create a better chance for successful smoking cessation.
These findings can inform development of health policies and strategies which target smoking cessation among young and middle-aged smokers.
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